Ten-year clinical outcomes of biodegradable versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus

Lenz T, Koch T, Joner M, Xhepa E, Wiebe J, Coughlan JJ, Aytekin A, Ibrahim T, Fusaro M, Cassese S, Laugwitz KL, Schunkert H, Kastrati A, Kufner S (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Journal of the American Heart Association Wiley

Book Volume: 10

Article Number: e020165

Journal Issue: 12

DOI: 10.1161/JAHA.120.020165

Abstract

BACKGROUND: Extended long-term follow-up data of new-generation drug-eluting stents in patients with diabetes mellitus is scant. The aim of this study is to assess the 10-year clinical outcome of new-generation biodegradable polymer-based sirolimus-eluting stents (Yukon Choice PC) versus permanent polymer-based everolimus-eluting stents (XIENCE) in patients with and without diabetes mellitus. METHODS AND RESULTS: In a prespecified subgroup analysis, outcomes of patients with or without diabetes mellitus treated with drug-eluting stents were compared. The primary end point of this analysis was major adverse cardiac event, the compos-ite of death, myocardial infarction, or target lesion revascularization. The analysis includes a total of 1951 patients (560 patients with and 1391 patients without diabetes mellitus) randomized to treatment with Yukon Choice PC (n=1299) or Xience (n=652). Regarding the primary end point, at 10 years patients with diabetes mellitus showed significantly higher major adverse cardiac event rates than patients without diabetes mellitus (P<0.001; hazard ratio [HR], 1.41; 95% CI, 1.22–1.63). There was no significant difference between patients treated with Yukon Choice PC versus Xience, neither in the subgroup of patients with (P=0.91; HR, 1.01; 95% CI, 0.79–1.30) nor without diabetes mellitus (P=0.50; HR, 0.94; 95% CI, 0.79–1.21). Rates of definite/ probable stent thrombosis were 2.3% in patients with and 1.9% in patients without diabetes mellitus (HR, 1.27; 95% CI, 0.34– 2.60; P=0.52), without significant differences between study devices. CONCLUSIONS: The clinical outcome of patients with diabetes after percutaneous coronary intervention with different new-generation drug-eluting stents is considerably worse than that of patients without diabetes mellitus, with event rates constantly increasing out to 10 years. REGISTRATION: URL: https://clini​caltr​ials.gov. Unique Identifier: NCT00598676.

Involved external institutions

Technische Universität München (TUM) DE Germany (DE)

How to cite

APA:

Lenz, T., Koch, T., Joner, M., Xhepa, E., Wiebe, J., Coughlan, J.J.,... Kufner, S. (2021). Ten-year clinical outcomes of biodegradable versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus. Journal of the American Heart Association, 10(12). https://doi.org/10.1161/JAHA.120.020165

MLA:

Lenz, Tobias, et al. "Ten-year clinical outcomes of biodegradable versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus." Journal of the American Heart Association 10.12 (2021).

BibTeX: Download